Cardiology

European Society of Hypertension :2023 Guideline Update

European Society of Hypertension : 2023 Guideline Update

The recently published European Society of Hypertension (ESH) 2023 ESH Guidelines for the management of arterial hypertension is the latest in a long series of high blood pressure (BP) clinical practice guidelines. It closely resembles the 2018 European Society of Cardiology/ESH guidelines, with incremental rather than major changes.

Modern Medicine – Issue 1 2024

Fenofibrate + Statin Found to ReduceDiabetic Retinopathy Progression

Fenofibrate + Statin Found to Reduce Diabetic Retinopathy Progression

Diabetic retinopathy is a significant cause of vision impairment and is predicted to become an increasingly large global public health problem. Diabetic retinopathy often affects those of working age and can have significant health, social and economic implications. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-a) agonist, has been suggested as an adjunctive therapeutic option for diabetic retinopathy in patients with diabetes and existent diabetic retinopathy.

Modern Medicine – Issue 6 2023

Heart Failure with Reduced Ejection Fraction: Advances in Management

Heart Failure with Reduced Ejection Fraction: Advances in Management

Heart failure (HF) is a leading cause of morbidity and a major burden on healthcare resources. Targeting modifiable risk factors and use of guideline-directed medical therapies in at-risk individuals is a crucial first step in the prevention of HF progression. All eligible patients with HF with reduced ejection fraction should be treated with the ‘big four’ pharmacological drug classes – angiotensin receptor neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists and SGLT-2 inhibitors – which have proven benefit in reducing cardiovascular mortality and HF hospitalisation.

Modern Medicine – Issue 6 2023

The Role of Beta-blockers: 2023 ESH Guidelines for Managing Arterial Hypertension

The Role of Beta-blockers: 2023 ESH Guidelines for Managing Arterial Hypertension

In June, the 2023 European Society of Hypertension (ESH) Hypertension guidelines were published. Overall, the new report closely resembles its predecessor published in 2018. The guidelines confirm the preferred use of renin–angiotensin system blockers, calcium channel blockers and Thiazide/Thiazide-like diuretics, and their various combinations, for blood pressure lowering treatment. Beta-blockers (BBs) are included among the major antihypertensive medications.

Modern Medicine – Issue 5 2023

Fluid Regulation is Vital inHypertension Management

Fluid Regulation is Vital in Hypertension Management

Fluid balance is inextricably linked with electrolyte balance, both in the intracellular (rich in K+ ions) and extracellular (rich in Na+ & Cl- ions) compartments, where trading of electrolytes is the core strategy of renal fluid regulation. Medicinal products that affect renal regulation of electrolyte excretion have a significant effect in terms of the quantity of fluid control and thus water homeostasis.

Modern Medicine – Issue 4 2023

Lipid Levels – Important Clues for Cardio and Pancreas Health

Lipid Levels – Important Clues for Cardio and Pancreas Health

Hypertriglyceridemia (HTG), as an important component of atherogenic dyslipidaemia and a cardiovascular disease risk factor, should be carefully evaluated and managed via lifestyle modification and pharmacotherapy. Although statins form a basis of the contemporary lipid-modifying treatment, major trials support the findings that therapy with fibrates is most beneficial in patients with triglyceride levels above 204mg/dL and high-density lipoprotein cholesterol (HDL-C) below 34mg/dL.

Modern Medicine – Issue 4 2023

Add-on Fibrates’ Cardio Protection
Still Evident Years On

Add-on Fibrates’ Cardio Protection Still Evident Years On

The extended follow-up study (ACCORDION) of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, evaluated the ‘legacy effects’ of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidaemia. Fibrate treatment during the initial trial period was associated with a legacy benefit of improved survival over a post-trial follow-up. This is a shortened version of the original article.

Modern Medicine – Issue 2 2023

Anticoagulation: Extended treatment
for venous thromboembolism

Anticoagulation: Extended treatment for venous thromboembolism

Indefinite anticoagulation with direct oral anticoagulants (DOACs) is increasingly being recommended after symptomatic venous thromboembolism (VTE) in many clinical scenarios. This is because of the ease of use and lower bleeding risk of DOACs compared with warfarin and cumulative evidence of recurrence risk if anticoagulants are stopped, particularly after unprovoked VTE. The decision for extended use should be tailored to each patient, based on the risk of recurrence and bleeding, and patient preference.

Modern Medicine – Issue 2 2023

Heart Failure: A Growing Problem
in Younger Patients

Heart Failure: A Growing Problem in Younger Patients

Heart failure (HF) is a major public health challenge, accounting for significant morbidity and premature mortality globally, including in sub-Saharan Africa (SSA). In contrast to Western countries, where HF is considered a disease of older persons, in SSA it affects younger individuals. Acute decompensated HF is the most common primary diagnosis for patients admitted to hospital with heart disease in SSA.

Modern Medicine – Issue 2 2023

Verified by ExactMetrics